The Amgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard ...
Amgen (NASDAQ:AMGN) remains a major biotechnology name as nasdaq composite discussions highlight healthcare innovation.
California healthcare innovator Amgen, which already has facilities at Cambridge Science Park, has made a new and incisive acquisition in the UK - buying Oxford University spin-out Dark Blue ...
Amgen is committed to reducing drug costs, expanding its AmgenNow program, and investing in US manufacturing to gain tariff ...
Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...
Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech’s preclinical blood cancer program into its ...
OXFORD, England, Jan. 6, 2026 /PRNewswire/ -- Dark Blue Therapeutics ("Dark Blue"), a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been ...
LASEC and the Los Angeles World Cup 2026 Host Committee Will Collaborate with Amgen to Amplify Community Health and Legacy Programs in Greater Los Angeles Ahead of Historic Sporting Events LOS ANGELES ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback